Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients

Study ID
NCT02812992

Study type
Interventional

Study phase
Phase 4

Study status
Completed

Trial Acronym

GrantPax

Trial Summary

The GrantPax study is a multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/- nab-paclitaxel in elderly pancreatic cancer patients. The primary objective is that CGA-stratified patients do not decline in their CGA performance in response to chemotherapy measured as a loss of five points or less in the Barthel's ADL, (ADL1 vs. ADL2 during core CGA assessment).

More informations

Trial Starting Date

Jun 30,2016

Requirements

Gender All
Minimum age 70 Years
Maximum age N/A

Enrollement Limit